350 reports of this reaction
4.2% of all SAPROPTERIN DIHYDROCHLORIDE reports
#3 most reported adverse reaction
THERAPY NON RESPONDER is the #3 most commonly reported adverse reaction for SAPROPTERIN DIHYDROCHLORIDE, manufactured by BioMarin Pharmaceutical Inc.. There are 350 FDA adverse event reports linking SAPROPTERIN DIHYDROCHLORIDE to THERAPY NON RESPONDER. This represents approximately 4.2% of all 8,360 adverse event reports for this drug.
Patients taking SAPROPTERIN DIHYDROCHLORIDE who experience therapy non responder should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
THERAPY NON RESPONDER is moderately reported among SAPROPTERIN DIHYDROCHLORIDE users, representing a notable but not dominant share of adverse events.
In addition to therapy non responder, the following adverse reactions have been reported for SAPROPTERIN DIHYDROCHLORIDE:
The following drugs have also been linked to therapy non responder in FDA adverse event reports:
THERAPY NON RESPONDER has been reported as an adverse event in 350 FDA reports for SAPROPTERIN DIHYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
THERAPY NON RESPONDER accounts for approximately 4.2% of all adverse event reports for SAPROPTERIN DIHYDROCHLORIDE, making it one of the most commonly reported side effect.
If you experience therapy non responder while taking SAPROPTERIN DIHYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.